pentobarbital will lower the level or effect of vinorelbine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.
pentobarbital will lower the level or influence of lapatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Induction of microsomal enzymes by this drug, may possibly shorten the 50 %-lifetime of doxycycline for as long as two weeks immediately after barbiturate therapy discontinued; check medical response to doxycycline closely if both drugs administered concurrently
pentobarbital will reduce the extent or impact of conivaptan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
Warning with use throughout surgical procedures or processes in young children younger than three yr or in pregnant Women of all ages for the duration of their 3rd trimester
pentobarbital will minimize the level or result of nicardipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lower the level or effect of osilodrostat is nembutal a cns depressant by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the extent or influence of estradiol by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
Contraindicated. The therapeutic influence of elbasvir/grazoprevir may very well be reduced if coadministered with powerful CYP3A inducers and is also for that reason contraindicated.
benzhydrocodone/acetaminophen and pentobarbital both raise sedation. Stay clear of or Use Alternate Drug. Restrict use to people for whom substitute cure choices are insufficient
pentobarbital and daridorexant both raise sedation. Modify Therapy/Monitor Closely. Coadministration raises threat of CNS depression, which may lead to additive impairment of psychomotor functionality and induce daytime impairment.
Check Closely (two)pentobarbital will lower the level or influence of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on. Robust CYP3A4 inducers may lower suvorexant efficacy; if improved suvorexant dose necessary, don't exceed 20 mg/working day
pentobarbital will minimize the level or influence of saxagliptin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known.
CYP3A4 inducers may well raise the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Intently keep an eye on individuals taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment.